Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat Tosylate + Pembrolizumab vs Pembrolizumab in 1L Advanced NSCLC
NCT06644768Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of valemetostat in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Oct 2024; status: active, not recruiting.
02
Drugs
valemetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06644768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644768.